Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.37)
# 4,299
Out of 5,152 analysts
17
Total ratings
26.67%
Success rate
-23.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $7.72 | +871.50% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.64 | +875.61% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $0.11 | +8,126.69% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.81 | +109.97% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $30.28 | +230.25% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.43 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $1.97 | +190,255.33% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.91 | +1,553.99% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.90 | +897.45% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.78 | +655.40% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $55.80 | +61.29% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.56 | +12,009.38% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.21 | +2,776,759.50% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $7.72
Upside: +871.50%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.64
Upside: +875.61%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $0.11
Upside: +8,126.69%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.81
Upside: +109.97%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $30.28
Upside: +230.25%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.43
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $1.97
Upside: +190,255.33%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.91
Upside: +1,553.99%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.90
Upside: +897.45%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.78
Upside: +655.40%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $55.80
Upside: +61.29%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.56
Upside: +12,009.38%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.21
Upside: +2,776,759.50%